ArticleJournal of clinical medicine2022
Comparison of Remimazolam-Flumazenil versus Propofol for Rigid Bronchoscopy: A Prospective Randomized Controlled Trial.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 6 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Comparative efficacy and safety of remimazolam versus propofol in bronchoscopic procedures: a GRADE-assessed systematic review and meta-analysis.BMC anesthesiology · 2026Pooled it
- The delirium dichotomy of remimazolam: a differential risk profile for emergence delirium versus postoperative delirium in surgical patients: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Pooled it
- Remimazolam vs propofol for postoperative delirium in adults undergoing general anesthesia: A meta-analysis.Biomolecules & biomedicine · 2025Pooled it
- Efficacy of remimazolam in preventing postoperative nausea and vomiting: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Safety and efficacy of remimazolam versus propofol sedation in gynecological procedures: a meta-analysis of East Asian randomized trials.Frontiers in medicine · 2025Pooled it
- Efficacy and safety of remimazolam tosilate in elderly patients undergoing general anesthesia for bronchoscopy. A randomized controlled trial.BMC anesthesiology · 2025Trial
- Remimazolam-Remifentanil versus Propofol-Remifentanil for Spontaneous Ventilation During Fiberoptic Bronchoscopy: A Randomized Controlled Trial.Current medical science · 2025Trial
- Comparison of the efficacy and safety of remimazolam and propofol for fiberoptic bronchoscopy in older patients: a prospective, randomized controlled study.BMC geriatrics · 2025Trial
- Emergence profiles of remimazolam-flumazenil versus propofol in pediatric general anesthesia for strabismus correction: a randomized clinical trial.BMC anesthesiology · 2025Trial
- Remimazolam-flumazenil provides fast recovery from general anesthesia compared to propofol during radiofrequency catheter ablation of atrial fibrillation.Scientific reports · 2024Trial
- Effect of converting from propofol to remimazolam with flumazenil reversal on recovery from anesthesia in outpatients with mental disabilities: a randomized controlled trial.BMC anesthesiology · 2024Trial
- Remimazolam Compared to Propofol for Total Intravenous Anesthesia with Remifentanil on the Recovery of Psychomotor Function: A Randomized Controlled Trial.Advances in therapy · 2023Trial
- Article
- Comparison of the safety and efficacy of remimazolamFrontiers in pharmacology · 2026Article
- What Is the Most Effective Strategy for Acute Postoperative Pain in Total Knee Arthroplasty-Retrospective Observational Study.Journal of clinical medicine · 2025Article
- Current and Developing Approaches for Facilitating Emergence from General Anesthesia.Anesthesiology · 2025Review
- Impact of Bispectral Index- and Target-Controlled Infusion-Guided Sedation on Patient Comfort and Procedural Workflow During Bronchoscopy.Healthcare (Basel, Switzerland) · 2025Article
- Article
- Anesthesia for Bronchoscopy-An Update.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
Background: Remimazolam is a novel ultrashort-acting intravenous benzodiazepine sedative−hypnotic that significantly reduces the times to sedation onset and recovery. This trial was conducted to confirm the recovery time from anesthesia of remimazolam-flumazenil versus propofol in patients undergoing endotracheal surgery under rigid bronchoscopy. Methods: Patients undergoing endotracheal tumor resection or stent implantation were randomly allocated into a remimazolam group (Group R) or a propofol group (Group P). The primary outcome was the recovery time from general anesthesia. The secondary outcomes were the time to loss of consciousness (LoC), hemodynamic fluctuations, and adverse events. Results: A total of 34 patients were screened, and 30 patients were enrolled in the study. The recovery time was significantly shorter for Group R (140 ± 52 s) than for Group P (374 ± 195 s) (p < 0.001). The times to LoC were 76 ± 40 s in Group R and 75 ± 25 s in Group P and were not significantly different. There were also no significant differences in hemodynamic fluctuations or adverse events between the two groups. Conclusions: The recovery time from general anesthesia in rigid bronchoscopy patients was shorter using remimazolam-flumazenil than with propofol, with no dramatic hemodynamic fluctuations and adverse events or differences between the agents. Remimazolam-flumazenil allows for faster recovery from anesthesia than propofol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.